Tech Company Inital Public Offerings
Liquidia Technologies IPO
Liquidia Technologies was acquired by . Shares were listed on 7/25/2018.
Transaction Overview
Company Name
Announced On
7/25/2018
Transaction Type
IPO
Amount
$50,000,000
Proceeds Purpose
Approximately $30.0 to $32.0 million to complete our ongoing Phase 3 clinical trial and other development work for LIQ861; approximately $1.2 to $1.8 million to advance LIQ865 through our planned Phase 2-enabling toxicology studies initiated in 2018; approximately $12.0 to $13.0 million to fund operations supporting the development and commercial activities for LIQ861 and LIQ865; and the remainder for working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
419 Davis Dr. 100
Morrisville, NC 27560
USA
Morrisville, NC 27560
USA
Phone
Website
Email Address
Overview
Liquidia's (Nasdaq: LQDA) technology is revolutionizing the development of engineered drug therapies for the diagnosis and treatment of human disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Neal Fowler
Chief Operating Officer
Robert Lippe
President
Kevin Gordon
Vice President
Jeri Thomas
VP - Bus. Development
Jason Adair
VP - Human Resources
Florina Gordon-Krawchick
VP - Product Management
Robert Roscigno
VP - R & D
Benjamin Maynor
Browse more venture capital transactions:
Prev: 7/24/2018: Volta Charging venture capital transaction
Next: 7/25/2018: MetroMile venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs